There’s more than one reason why experts are excited by the potential of CSL. The post Here's one reason why experts think ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working ...

CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The expansion, a cornerstone of the ...

CSL's strong building products portfolio and efficient capital allocation support stable margins, but certain headwinds limit growth opportunities. Recurring re-roofing revenues and operational ...

Are the biotech company's shares worth holding onto? The post $5,000 invested in CSL shares 12 months ago is now worth… ...

Brokers see significantly more upside ahead for Pro Medicus. The post Forget CSL shares, this ASX healthcare stock could ...

CSL to downsize one-third of R&D division, AFR reports Company has not confirmed the number of job reductions Shares up 3% at over 6-week high July 15 (Reuters) - Australian biotech giant CSL Ltd (CSL ...

Business remains robust and brokers see ASX stock soaring up to 100%. The post CSL shares look primed to take off — Here's ...

The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines "CSL's growing R&D presence in Waltham is the latest example of our ...

CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...

SYDNEY--Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.